Scaling-up and production of therapeutic antibodies for preclinical studies.
Monoclonal antibodies are increasingly used for treatment of various diseases, mostly cancer therapy and auto-immune diseases. New chimeric, humanized, or fully-human antibodies specific to novel or already validated targets are being developed in many academic labs as well as in commercial entities. A validation of antibodies in preclinical settings is an important component of the road from discovery to clinic. Preparing sufficient amount of high-quality antibodies for preclinical studies is a challenge in some cases. This article summarizes protocols used in research laboratories, and is based on our own experience in the establishment of stable clones of CHO cells to scaling-up of tissue cultures for production of antibodies in bioreactors.
Feng
Yang
Y
NCI-Frederick, National Institutes of Health, Frederick, MD, USA.
Dimitrov
Dimiter S
DS
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D019149:Bioreactors; D016466:CHO Cells; D002999:Clone Cells; D006224:Cricetinae; D003412:Cricetulus; D016895:Culture Media, Serum-Free; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D013347:Subcellular Fractions
D000906:Antibodies; D016895:Culture Media, Serum-Free